Technetium Containing (at. No. 43; Tc) Patents (Class 534/14)
-
Patent number: 7320784Abstract: The invention includes methods and compounds for labelling conjugates with metals which comprise the steps of coupling the conjugate to a support surface; introducing a complex-forming metal to the support; and collecting the metal-conjugate complex released from the support. The metal catalyzes cleavage of the conjugate from the support upon complex formation resulting in a solutions substantially free of unlabeled conjugate.Type: GrantFiled: August 3, 1999Date of Patent: January 22, 2008Assignee: Bracco Imaging S.p.A.Inventors: Alfred Pollak, David Roe, Linda Fung Lu, John Thornback, Catherine M. Pollock
-
Publication number: 20070286802Abstract: The present invention is to invent a novel method for testing the radiochemical purity of Tc-99m-TRODAT-1 through a high performance liquid chromatography on a widely available C-18 column.Type: ApplicationFiled: June 8, 2006Publication date: December 13, 2007Applicant: ATOMIC ENERGY COUNCIL-INSTITUTE OF NUCLEAR ENERGY RESEARCHInventors: Yu-Chin Tseng, Yuen-Han Yeh, Mei-Chih Wu, Lie-Hang Shen
-
Patent number: 7268220Abstract: The present invention provides for substituted metal chelating compounds in which at least two of the chelating atoms are nitrogen which are directly attached to aromatic rings and one or more of those nitrogen atoms has attached thereto a substituent other than hydrogen, and methods for making and using these compounds.Type: GrantFiled: February 18, 2005Date of Patent: September 11, 2007Assignee: Poniard Pharmaceuticals, Inc.Inventor: Sudhakar Kasina
-
Patent number: 7238339Abstract: New types of hydroxamic acid-based bifunctional chelators are provided. These chelators are designed to chelate metal ions that can be detected either by their paramagnetic or radioactive properties. Conjugation with peptides or protein can be achieved by the presence of a linker moiety in the molecular structure of these chelators.Type: GrantFiled: August 4, 2003Date of Patent: July 3, 2007Assignee: DRAXIS Specialty Pharmaceuticals Inc.Inventor: Jean-Marc DuFour
-
Publication number: 20070140959Abstract: Disclosed herein is a method of preparing a 188Re-tricarbonyl complex for radiopharmaceutical use and of preparing a precursor thereof, and a contrast agent using the same. Particularly, this invention provides a method of preparing a 188Re-tricarbonyl precursor by reacting perrhenate with borane-ammonia (BH3.NH3), potassium boranocarbonate (K2[H3BCO2]) and phosphate in the presence of borohydride exchange resin as a reducing agent, and a method of preparing a 188Re-tricarbonyl complex by reacting the 188Re-tricarbonyl precursor with a ligand. According to the method of this invention, the borohydride exchange resin is used as a reducing agent and as an anion scavenger, thereby obtaining the 188Re-tricarbonyl precursor and complex having high radiolabeling yield and high purity. In addition, the 188Re-tricarbonyl complex can be used as a contrast agent having excellent plasma stability.Type: ApplicationFiled: June 20, 2006Publication date: June 21, 2007Inventors: Sang Hyun Park, Seung Ho Jang, Myung Woo Byun
-
Patent number: 7211241Abstract: Described are new cascade polymer complexes, compositions containing them and use of the complexes in diagnosis and therapy, particularly for magnetic resonance imaging and computer tomography imaging.Type: GrantFiled: October 17, 2003Date of Patent: May 1, 2007Assignee: Schering AktiengesellschaftInventors: Heribert Schmitt-Willich, Johannes Platzek, Bernd Radüchel, Andreas Mühler, Thomas Frenzel
-
Patent number: 7186400Abstract: Compounds of general formula (I): in which: R1 is hydrogen, C1–C20 alkyl, C3–C10 cycloalkyl, C4–C20 cycloalkylalkyl, aryl, arylalkyl, or two R1, taken together, form a straight or cyclic C2–C10 alkylene group or an ortho disubstituted arylene; R2 is hydrogen, C1–C20 alkyl, C3–C10 cycloalkyl, C4–C20 cycloalkylalkyl, aryl or aryl alkyl optionally substituted with functional groups which allow conjugation with a suitable molecule able to interact with physiological systems; R3, R4 and R5 are hydrogen, C1–C20 alkyl, C3–C10 cycloalkyl, C4–C20 cycloalkylalkyl, aryl, arylalkyl; and their chelates with bi-trivalent ions of the metal elements having atomic number ranging between 20 and 31, 39, 42, 43, 44, 49, and between 57 and 83, and radioisotopes chosen among 203Pb 67Ga 68Ga 72As 111In 113In 90Y 97Ru 62Cu 64Cu 52Fe 52mMn 140La 175Yb 153Sm 166Ho 149Pm 177Lu 142Pr 159Gd 212Bi 47Sc 149Pm 67Cu, 111Ag, 199Au, 161Tb and 51Cr as well as the salts thereof with physiologically compatible bases or acidsType: GrantFiled: July 10, 2002Date of Patent: March 6, 2007Assignee: Bracco Imaging S.p.A.Inventors: Giovanni Battista Giovenzana, Giovanni Palmisano, Massimo Sisti, Camilla Cavallotti, Silvio Aime, Luisella Calabi
-
Patent number: 7179444Abstract: The disclosure provides pendant fatty acid compounds for use in diagnostic imaging, (particularly the cardiovascular system), as well as kits comprised of the same. The disclosure also provides for a method administering a imaging agent with a high specificity for the myocardium.Type: GrantFiled: April 1, 2003Date of Patent: February 20, 2007Assignee: Molecular Insight Pharmaceuticals, Inc.Inventor: John W. Babich
-
Patent number: 7179445Abstract: The invention provides detectably labeled cobalamin derivatives which are useful for medical treatment and diagnosis.Type: GrantFiled: February 24, 2004Date of Patent: February 20, 2007Assignees: Mayo Foundation for Medical Education and Research, Regents of the University of MinnesotaInventors: Douglas A. Collins, Henricus P. C. Hogenkamp
-
Patent number: 7166719Abstract: Provided herein are compounds for detection, diagnosis and treatment of target tissues or target compositions, including hyperproliferative tissues such as tumors, using photodynamic methods. In particular, photosensitizer compounds that collect in hyperproliferative tissue are provided. In another embodiment, compounds that absorb light at a wavelength of from about 700 to about 850 nm are provided. In a further embodiment, compounds that are detectable by magnetic resonance imaging are provided.Type: GrantFiled: June 27, 2003Date of Patent: January 23, 2007Assignee: Health Research, Inc.Inventors: Ravindra K. Pandey, William R. Potter, Thomas J. Dougherty
-
Patent number: 7163935Abstract: Substituted 1,4,7-triazacyclononane-N,N?,N?-triacetic acid compounds with a pendant donor amino group, metal complexes thereof, compositions thereof, and methods of use in diagnostic imaging and treatment of a cellular disorder.Type: GrantFiled: June 3, 2003Date of Patent: January 16, 2007Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Martin W. Brechbiel, Hyun-Soon Chong
-
Patent number: 7138104Abstract: The present invention describes a method of concurrent imaging in a mammal comprising: a) administering to said mammal a vitronectin receptor targeted imaging agent and a perfusion imaging agent; and b) concurrently detecting the vitronectin receptor targeted imaging agent bound at the vitronectin receptor and the perfusion imaging agent; and c) forming an image from the detection of said vitronectin targeted imaging agent and said perfusion imaging agent.Type: GrantFiled: August 7, 2002Date of Patent: November 21, 2006Assignee: Bristol-Myers Squibb CompanyInventor: Alan P. Carpenter, Jr.
-
Patent number: 7115720Abstract: The invention provides a complex comprising a) a compound formula I: wherein R1, X and n have any of the values described in the specification, or a pharmaceutically acceptable salt thereof; and b) a radionuclide. The complexes are useful as diagnostic agents and as therapeutic agents. The invention also provides methods and intermediates useful for preparing the complexes of the invention, as well as therapeutic and diagnostic methods.Type: GrantFiled: July 8, 2003Date of Patent: October 3, 2006Assignee: Neorx CorporationInventor: Alan R. Fritzberg
-
Patent number: 7097826Abstract: A compound comprising a chemical combination of a photodynamic tetra-pyrrolic compound with a plurality of radionuclide element atoms such that the compound may be used to enhance MR imaging and also be used as a photodynamic compound for use in photodynamic therapy to treat hyperproliferative tissue. The preferred compounds have the structural formula: where R1, R2, R2a R3, R3a R4, R5, R5a R6, R7, R7a, and R8 cumulatively contain at least two functional groups that will complex or combine with an MR imaging enhancing element or ion. The compound is intended to include such complexes and combinations and includes the use of such compounds for MR imaging and photodynamic therapy treatment of tumors and other hyperproliferative tissue.Type: GrantFiled: June 21, 2002Date of Patent: August 29, 2006Assignee: Health Research, Inc.Inventors: Ravindra K. Pandey, Zachary Grossman, Peter Kanter, Thomas J. Dougherty
-
Patent number: 7090828Abstract: The present invention describes novel compounds of the formula: (Q)d-Ln-Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety.Type: GrantFiled: January 21, 2003Date of Patent: August 15, 2006Assignee: Bristol-Myers Squibb Pharma CompanyInventors: Edward H. Cheesman, John A. Barrett, Alan P. Carpenter, Jr., Milind Rajopadhye, Michael Sworin
-
Patent number: 7081452Abstract: Substituted 1,4,7-triazacyclononane-N,N?,N?-triacetic acid compounds with a pendant donor amino group, metal complexes thereof, compositions thereof, and methods of use in diagnostic imaging and treatment of a cellular disorder.Type: GrantFiled: December 13, 2002Date of Patent: July 25, 2006Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Martin W. Brechbiel, Hyun-Soon Chong
-
Patent number: 7052673Abstract: The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.Type: GrantFiled: July 18, 2003Date of Patent: May 30, 2006Assignee: Bristol-Myers Squibb Pharma CompanyInventors: Milind Rajopadhye, D. Scott Edwards, John A. Barrett, Alan P. Carpenter, Jr., Thomas D Harris, Stuart D Heminway, Shuang Liu, Singh R Prahlad
-
Patent number: 7048907Abstract: Stable isotope labeling and neutron activation to measure biological functions are provided, as are the use and method of adding a chemical monitor to correct for neutron flux to sample vials prior to the addition of sample is presented, and the use of stable isotopes as a chemical bar code for vials and other items. Methods are provided also for measuring glomerular filtration rate and glomerular sieving function in a subject, and for measuring other physiological functions.Type: GrantFiled: January 30, 2002Date of Patent: May 23, 2006Assignee: BioPhysics Assay Laboratory, Inc.Inventors: Ernest V. Groman, Christopher P. Reinhardt
-
Patent number: 7018612Abstract: The invention relates to a method of preparing a solution of a radioactive rhenium complex, by reacting at elevated temperature a radioactive perrhenate in a substantially aqueous solution with a ligand in the presence of a reductant and optionally an antioxidant under substantially anaerobic conditions, wherein said reaction is carried out at a pH from approx. 1.5 to approx. 5 and by heating the reaction components for at least 10 min. at a temperature of at least 100° C. The invention further relates to a kit for performing said method.Type: GrantFiled: July 2, 1991Date of Patent: March 28, 2006Assignee: Mallinckrodt Inc.Inventors: Helena Panek-Finda, David W. Pipes
-
Patent number: 7018611Abstract: The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety.Type: GrantFiled: October 26, 2002Date of Patent: March 28, 2006Assignee: Bristol-Myers Squibb Pharma CompanyInventors: Thomas D. Harris, John A. Barrett, Alan P. Carpenter, Jr., Milind Rajopadhye
-
Patent number: 7012140Abstract: The present invention is directed, in general, to a contrast agent comprising a tetraazacyclododecane ligand and comprising a macrocyclic ring and a paramagnetic metal ion coordinated to the tetraazacyclododecane ligand. Pendent arms R, R?, R? and R?? attached to a ring nitrogen. The pendent arms have the general formula: ?C?HR1R2 and for three or more of the pendant arms a chirality of the carbon atoms C? are identical for each of three or more of the pendant arms. The R1 group is larger than hydrogen and R2 is selected from the group consisting of: an alcohol, amides, a carboxylate, phosphinates and a phosphonate. One or more substituents R6 is a group larger than a methyl group and is located on one or more ring carbons.Type: GrantFiled: July 14, 2003Date of Patent: March 14, 2006Assignees: Board of Regents, The University of Texas System, MacrocyclicsInventors: A. Dean Sherry, Mark Woods, Zoltan Kovacs
-
Patent number: 6979436Abstract: Metallopeptides and metallopeptide combinatorial libraries specific for opioids receptors are provided, for use in biological, pharmaceutical and related applications. The metallopeptides and combinatorial libraries are made of peptides, peptidomimetics and peptide-like constructs, in which the peptide, peptidomimetic or construct is conformationally fixed in a biologically active configuration specific for one or more opioid receptors on complexation of a metal ion-binding portion thereof with a metal ion.Type: GrantFiled: May 17, 2002Date of Patent: December 27, 2005Assignee: Palatin Technologies, Inc.Inventors: Shubh D. Sharma, Wei Yang, Hui-Zhi Cai
-
Patent number: 6962690Abstract: Fluorescent chelates of lanthanide, terbium, europium and dysprosium with tetraazamacrocyclic compounds are discussed which can be used as fluorescent in vitro or in vivo diagnostic agents. These chelates are tissue specific imaging agents for soft tissue cancers.Type: GrantFiled: October 22, 2002Date of Patent: November 8, 2005Assignees: Dow Global Technologies Inc., Texas Tech UniversityInventors: Garry E. Kiefer, Darryl J. Bornhop
-
Patent number: 6958141Abstract: Novel methods, processes and metal complexes attached to a hypoxia-localizing moiety comprising a metal, preferably radionuclide of rhenium or technetium; a hypoxia-localizing moiety; and, a complexing ligand, wherein said ligand and said radionuclide combined have cell membrane permeabilities greater than that of sucrose, are disclosed.Type: GrantFiled: December 19, 2003Date of Patent: October 25, 2005Assignee: Bracco International B.V.Inventors: Karen Linder, Adrian D. Nunn, David P. Nowotnik, Kondareddiar Ramalingam, Richard J. DiRocco, William L. Rumsey, John P. Pirro
-
Patent number: 6951640Abstract: The present invention covers halogenated derivatives of boronated phorphyrins containing multiple carborane cages having the formula which selectively accumulate in neoplastic tissue within the irradiation volume and thus can be used in cancer therapies including, but not limited to, boron neutron-capture therapy and photodynamic therapy. The present invention also covers methods for using these halogenated derivatives of boronated porphyrins in tumor imaging and cancer treatment.Type: GrantFiled: February 27, 2003Date of Patent: October 4, 2005Assignee: Brookhaven Science Associates, LLCInventors: Michiko Miura, Daniel N. Slatkin
-
Patent number: 6936240Abstract: The present invention relates to a method of preparing technetium or rhenium complex for radiopharmaceuticals, through reaction of pertechnetate or perrhenate with a ligand in the presence of a reducing agent, wherein the reducing agent is a borohydride exchange resin (BER). The borohydride exchange resin of the present invention has advantages of being stable in a wide range of Ph, including acidic or alkaline condition(Ph 2˜14) and thus being applicable to biological materials as well as being easily removable through filtration when being administrated. Also since the radiolabelled complex is produced under conditions milder than those required for the conventional reducing agents as well as has high radiochemical purity and high labeling efficiency, the conventional reducing agents can be replaced by the BER of the present invention.Type: GrantFiled: October 31, 2002Date of Patent: August 30, 2005Assignee: Korea Atomic Energy Research InstituteInventors: Kyung Bae Park, Sang Hyun Park, Hui Jeong Gwon, Sun Ju Choi, Byung Chul Shin, Young Don Hong, Sang Mu Choi, Woong Woo Park, Kwang Hee Han, Beom Su Jang
-
Patent number: 6936700Abstract: The present invention provides for substituted metal chelating compounds in which at least two of the chelating atoms are nitrogen which are directly attached to aromatic rings and one or more of those nitrogen atoms has attached thereto a substituent other than hydrogen, and methods for making and using these compounds.Type: GrantFiled: January 17, 2003Date of Patent: August 30, 2005Assignee: NeoRx CorporationInventor: Sudhakar Kasina
-
Patent number: 6926883Abstract: The invention relates to novel aminocarboxylate ligands that are suitable for complexing with a radionuclide, and are useful as imaging agents for diagnostic purposes. In accordance with the present invention, a method of preparing a compound of formula (I): fac-[M(CO)3(OH2)3]+, wherein M is Mn, 99mTc, 186Re or 188Re, involves reacting a metal in permetallate form with carbon monoxide and a reducing agent, wherein a mixture of a basic borate buffer and a reducing agent soluble in water but not substantially decomposed by water is solved in a water containing solvent system containing a solution of the metal in permanganate, pertechnetate or perrhenate form in the presence of carbon monoxide. The compound of formula (I) can be reacted with a ligand Lx to form a compound of formula (II): fac-[M(CO)3(X)2L1]n, wherein M is as defined above Lx is a multidentate ligand, and n is a charge of the ligand Lx increased with one + charge.Type: GrantFiled: June 28, 2000Date of Patent: August 9, 2005Assignee: Mallinckrodt IncInventors: Mary M. Dyszlewski, Roger Alberto, Joseph E. Bugaj
-
Patent number: 6916460Abstract: This invention relates to macrocyclic chelants comprised of one or two heteroatom-containing bridges, compositions containing them and their use in medicine, particularly in diagnostic imaging and radiotherapy. This invention relates especially to the use of metal chelates of the macrocyclic chelants as metallopharmaceuticals in Magnetic Resonance Imaging (MRI) and radiopharmaceuticals. This invention also relates to macrocyclic chelants as bifunctional chelating agents (BFC's) for the labeling of biologically active targeting molecules such as proteins, peptides, peptidomimetics, and non-peptide receptor ligands, with metal ions and radioisotopes.Type: GrantFiled: September 15, 2003Date of Patent: July 12, 2005Assignee: Bristol-Myers Squibb Pharma CompanyInventor: Shuang Liu
-
Patent number: 6896871Abstract: The present invention is directed to particular bisphosphonate compounds, and in particular, to bisphosphonate conjugates that are useful in the treatment of soft tissues surrounding bone and bone-related diseases, such as bone cancer and osteoporosis.Type: GrantFiled: April 10, 2001Date of Patent: May 24, 2005Assignee: MBC Research, Inc.Inventors: Alexander Karpeisky, Nelly Padioukova, Sergey Mikhailov, H.B.F. Dixon, Grigorii Tzeitline, Marat Karpeisky
-
Patent number: 6890513Abstract: The present invention relates to a new method for the preparation of radiopharmaceuticals based on technetium and rhenium. The method involves the reaction of a salt of the formula [M(CO)3(Xm)3](1+3m), wherein M is selected from a radioisotope of rhenium, technetium and any other radioisotope that binds in a similar fashion, X is any suitable ligand and m is the formal charge for ligand X, with a nido-dicarbollide dianion of the formula [nido-(C2B9H11)]2? and functional derivatives thereof. The method has been shown to be applicable to the preparation of radiopharmaceuticals at the tracer level.Type: GrantFiled: May 24, 2002Date of Patent: May 10, 2005Assignee: McMaster UniversityInventors: John F Valliant, Pierre Morel, Paul Schaffer, Oyebola O. Sogbein
-
Patent number: 6869590Abstract: Detectably labeled macrophage scavenger receptor antagonists useful for the diagnosis and monitoring of various cardiovascular diseases including but not limited to atherosclerosis, vulnerable plaque, coronary artery disease, renal disease, thrombosis, transient ischemia due to clotting, stroke, myocardial infarction, organ transplant, organ failure and hypercholesterolemia.Type: GrantFiled: February 22, 2002Date of Patent: March 22, 2005Assignee: Bristol-Myers Squibb Pharma CompanyInventors: David Scott Edwards, Shuang Liu
-
Patent number: 6838073Abstract: The invention provides detectably labeled cobalamin derivatives which are useful for medical treatment and diagnosis.Type: GrantFiled: October 16, 2000Date of Patent: January 4, 2005Assignees: Mayo Foundation for Medical Education and Research, Regents of the University of MinnesotaInventors: Douglas A. Collins, Henricus P. C. Hogenkamp
-
Patent number: 6838074Abstract: The present invention describes a method of concurrent imaging in a mammal comprising: a) administering to said mammal a vitronectin receptor targeted imaging agent and a perfusion imaging agent; and b) concurrently detecting the vitronectin receptor targeted imaging agent bound at the vitronectin receptor and the perfusion imaging agent; and c) forming an image from the detection of said vitronectin targeted imaging agent and said perfusion imaging agent.Type: GrantFiled: August 7, 2002Date of Patent: January 4, 2005Assignee: Bristol-Myers Squibb CompanyInventor: Alan P. Carpenter, Jr.
-
Publication number: 20040260073Abstract: One aspect of the present invention relates to a method of purifying radiolabelled compounds comprising a) loading onto a fluorous polymer a radiolabelled compound precursor comprising a fluoroalkyl tin moiety; b) reacting the radiolabelled compound precursor with a radiolabel delivering compound to give a radiolabelled compound, wherein the fluoroalkyl tin moiety is replaced by a radiolabel; and c) eluting the radiolabelled compound from the fluorous polymer.Type: ApplicationFiled: October 16, 2003Publication date: December 23, 2004Inventors: John F. Valliant, Peter N. Dorff, Raman Chirakal
-
Publication number: 20040247523Abstract: The present invention provides novel diagnostic compositions comprising a radiolabeled LTB4 binding agent and a radiolabeled perfusion imaging agent, diagnostic kits comprising such compositions, and methods of concurrent imaging in a mammal comprising administering a radiolabeled LTB4 binding agent and a radiolabeled perfusion imaging agent, and concurrently detecting the radiolabeled LTB4 binding agent bound at the LTB4 receptor and the radiolabeled perfusion imaging agent.Type: ApplicationFiled: June 10, 2004Publication date: December 9, 2004Applicant: Bristol-Myers Squibb Pharma CompanyInventor: Alan P. Carpenter
-
Patent number: 6818201Abstract: The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety.Type: GrantFiled: November 26, 2002Date of Patent: November 16, 2004Assignee: Bristol-Myers Squibb Pharma CompanyInventors: Edward H. Cheesman, Michael Sworin, Milind Rajopadhye
-
Patent number: 6808698Abstract: A method wherein a radiolabelled compound is localized at a thrombus. Two-dimensional images, representing a physical property associated with the radiolabelled thrombus, are acquired and assembled into a three-dimensional matrix of data. The three-dimensional matrix of data is then scanned along an array of parallel lines to determine a maximum value along each line. The maximum value along each line is then assigned to a pixel in a two-dimensional array, where the relative position of the pixel in the two-dimensional array corresponds to the relative position of the line in the array of parallel lines.Type: GrantFiled: March 24, 2000Date of Patent: October 26, 2004Assignee: Bristol-Myers Squibb Pharma CompanyInventor: Joel Lazewatsky
-
Publication number: 20040208822Abstract: A compound of formula corresponding to either formula (Ia) or (Ib): 1Type: ApplicationFiled: May 12, 2004Publication date: October 21, 2004Inventors: Jean-Claude Madelmont, Isabelle Giraud, Colette Nicolas, Jean-Claude Maurizis, Maryse Rapp, Monique Ollier, Pierre Renard, Daniel-Henri Caignard
-
Patent number: 6800273Abstract: The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.Type: GrantFiled: January 14, 2003Date of Patent: October 5, 2004Assignee: Bristol-Myers Squibb Pharma CompanyInventors: Milind Rajopadhye, D. Scott Edwards, John A. Barrett, Alan P. Carpenter, Jr., Thomas D. Harris, Stuart J. Heminway, Shuang Liu, Prahlad R. Singh
-
Patent number: 6770259Abstract: The present invention provides novel diagnostic compositions comprising a radiolabeled LTB4 binding agent and a radiolabeled perfusion imaging agent, diagnostic kits comprising such compositions, and methods of concurrent imaging in a mammal comprising administering a radiolabeled LTB4 binding agent and a radiolabeled perfusion imaging agent, and concurrently detecting the radiolabeled LTB4 binding agent bound at the LTB4 receptor and the radiolabeled perfusion imaging agent.Type: GrantFiled: November 2, 2001Date of Patent: August 3, 2004Assignee: Bristol-Myers Squibb Pharma CompanyInventor: Alan P. Carpenter, Jr.
-
Patent number: 6749832Abstract: Compounds of formula (I) where: X1 is OH or SH or NH2 or —L-Z; X2 and X3 are the same or different and each is H, C1-4 alkyl, benzyl a protecting group or —L-Z, X4 is H or C1-4 alkyl, L is a linker comprising a chain of 0-10 atoms, Z is a group comprising a detectable moiety which comprise at least one detectable moiety are useful in the diagnosis and prognosis and radiotherapy of metastatic bone disease.Type: GrantFiled: September 16, 2002Date of Patent: June 15, 2004Assignee: Amersham PLCInventors: Susan Champion, Richard Pither
-
Publication number: 20040102632Abstract: Emissive phosphorescent organometallic compounds that produce electroluminescence and organic light emitting devices employing such emissive phosphorescent organometallic compounds are provided. More specifically the present invention is directed to novel primarily non-emitting ligands which produce a blue shift in emitted light when associated with a cyclometallated ligand.Type: ApplicationFiled: August 18, 2003Publication date: May 27, 2004Inventors: Mark E. Thompson, Peter Djurovich, Jian Li
-
Publication number: 20040082767Abstract: The invention provides radiopharmaceuticals for diagnostic and therapeutic applications, conjugates of antioxidants with metal chelating ligands, intermediate compounds, methods of making such radiopharmaceuticals, ligands, and intermediate compounds, and kits for preparing the radiopharmaceutical complexes.Type: ApplicationFiled: August 15, 2003Publication date: April 29, 2004Inventors: Ramachandra S. Ranganathan, Helen Fan, Michael F. Tweedle
-
Publication number: 20040057900Abstract: Detectably labeled macrophage scavenger receptor antagonists useful for the diagnosis and monitoring of various cardiovascular diseases including but not limited to atherosclerosis, vulnerable plaque, coronary artery disease, renal disease, thrombosis, transient ischemia due to clotting, stroke, myocardial infarction, organ transplant, organ failure and hypercholesterolemia.Type: ApplicationFiled: August 14, 2003Publication date: March 25, 2004Inventors: David Scott Edwards, Shuang Liu
-
Patent number: 6699458Abstract: Novel methods, processes and metal complexes attached to a hypoxia-localizing moiety comprising a metal, preferably radionuclide of rhenium or technetium; a hypoxia-localizing moiety; and, a complexing ligand, wherein said ligand and said radionuclide combined have cell membrane permeabilities greater than that of sucrose, are disclosed.Type: GrantFiled: November 16, 2001Date of Patent: March 2, 2004Assignee: Bracco International B.V.Inventors: Karen Linder, Adrian D. Nunn, David P. Nowotnik, Kondareddiar Ramalingam, Richard J. DiRocco, William L. Rumsey, John P. Pirro
-
Patent number: 6692724Abstract: The invention provides, in a general sense, a new labeling strategy employing 99mTc chelated with ethylenedicysteine (EC). EC is conjugated with a variety of ligands and chelated to 99mTc for use as an imaging agent for tissue-specific diseases. The drug conjugates of the invention may also be used as a prognostic tool or as a tool to deliver therapeutics to specific sites within a mammalian body. Kits for use in tissue-specific disease imaging are also provided.Type: GrantFiled: October 25, 1999Date of Patent: February 17, 2004Assignee: Board of Regents, The University of Texas SystemInventors: David J. Yang, Chun W. Liu, Dong-Fang Yu, E. Edmond Kim
-
Patent number: 6685914Abstract: This invention relates to macrocyclic chelants comprised of one or two heteroatom-containing bridges, compositions containing them and their use in medicine, particularly in diagnostic imaging and radiotherapy. This invention relates especially to the use of metal chelates of the macrocyclic chelants as metallopharmaceuticals in Magnetic Resonance Imaging (MRI) and radiopharmaceuticals. This invention also relates to macrocyclic chelants as bifunctional chelating agents (BFC's) for the labeling of biologically active targeting molecules such as proteins, peptides, peptidomimetics, and non-peptide receptor ligands, with metal ions and radioisotopes.Type: GrantFiled: September 12, 2000Date of Patent: February 3, 2004Assignee: Bristol-Myers Squibb Pharma CompanyInventor: Shuang Liu
-
Publication number: 20040018147Abstract: A radiopharmaceutical for diagnostic imaging containing as an active ingredient a technetium-99m nitride heterocomplex comprising technetium-99m nitride and two different ligands coordinated therewith, i.e., a bisphosphinoamine compound as a &pgr; electron acceptor and a bidentate ligand as a &pgr; electron donor and represented by the following formula (I): [99mTc(N)(PNP)(XY)]+ (I)wherein 99mTc(N) is technetium-99m nitride, PNP is a bisphosphinoamine compound and XY is a bidentate ligand, is markedly accumulated in heart and adrenal glands and hence is useful for radiodiagnostic imaging of heart and adrenal glands.Type: ApplicationFiled: September 4, 2003Publication date: January 29, 2004Inventors: Adriano Duatti, Cristina Bolzati, Licia Uccelli, Alessandra Boschi, Fiorenzo Refosco, Francesco Tisato
-
Patent number: 6669925Abstract: The present invention provides novel sigma-2 ligands (labeled and unlabeled) and the use of the compounds in medical therapy or diagnosis.Type: GrantFiled: April 27, 2001Date of Patent: December 30, 2003Assignee: Wake Forest UniversityInventors: Robert H. Mach, Kenneth T. Wheeler